AAPL334.51+2.24 (+0.67%) ▲|ABBV261.68+4.56 (+1.77%) ▲|ABT102.95+1.00 (+0.98%) ▲|ACN194.28+10.38 (+5.64%) ▲|ADBE264.86+12.63 (+5.01%) ▲|AMAT426.96-29.53 (-6.47%) ▼|AMD494.09-22.05 (-4.27%) ▼|AMGN380.37+3.02 (+0.80%) ▲|AMT177.20-0.65 (-0.37%) ▼|AMZN255.59-1.19 (-0.46%) ▼|AVGO346.64-15.36 (-4.24%) ▼|AXP326.91+2.22 (+0.68%) ▲|BA210.37-0.09 (-0.04%) ▼|BAC60.11-2.59 (-4.12%) ▼|BKNG175.20+1.28 (+0.74%) ▲|BLK1,066.89-12.76 (-1.18%) ▼|BMY64.12+0.48 (+0.75%) ▲|BNY158.30-4.36 (-2.68%) ▼|BRK-B513.81+3.44 (+0.67%) ▲|C133.83-4.99 (-3.59%) ▼|CAT786.08-32.50 (-3.97%) ▼|CL88.34+1.54 (+1.77%) ▲|CMCSA24.98-0.22 (-0.87%) ▼|COF207.37-0.94 (-0.45%) ▼|COP137.69+0.34 (+0.25%) ▲|COST917.05+12.28 (+1.36%) ▲|CRM258.90+11.18 (+4.51%) ▲|CSCO111.49-0.65 (-0.58%) ▼|CVS95.67+1.01 (+1.07%) ▲|CVX213.68-0.39 (-0.18%) ▼|DE681.39+5.65 (+0.84%) ▲|DHR203.41+3.27 (+1.63%) ▲|DIS109.18+2.63 (+2.47%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.37-3.82 (-2.51%) ▼|FDX311.61+0.84 (+0.27%) ▲|GD356.78+0.88 (+0.25%) ▲|GE317.29-6.38 (-1.97%) ▼|GEV873.25-84.02 (-8.78%) ▼|GILD145.74+2.02 (+1.41%) ▲|GM86.41+0.79 (+0.92%) ▲|GOOG345.45+10.00 (+2.98%) ▲|GOOGL348.92+10.42 (+3.08%) ▲|GS990.42-38.76 (-3.77%) ▼|HD310.54+1.80 (+0.58%) ▲|HON199.12-3.25 (-1.60%) ▼|IBM250.89+7.60 (+3.12%) ▲|INTC98.29-4.66 (-4.52%) ▼|INTU338.38+16.81 (+5.23%) ▲|ISRG376.21+7.06 (+1.91%) ▲|JNJ267.88+2.30 (+0.87%) ▲|JPM349.21-7.02 (-1.97%) ▼|KO89.14+0.85 (+0.96%) ▲|LIN464.53-1.70 (-0.36%) ▼|LLY1,145.82+30.12 (+2.70%) ▲|LMT527.84+3.65 (+0.70%) ▲|LOW198.37+1.55 (+0.79%) ▲|LRCX275.82-22.41 (-7.51%) ▼|MA575.04+5.85 (+1.03%) ▲|MCD257.19+4.66 (+1.85%) ▲|MDLZ62.38-0.06 (-0.10%) ▼|MDT93.31+2.35 (+2.58%) ▲|META664.45+16.42 (+2.53%) ▲|MMM162.01-2.96 (-1.79%) ▼|MO70.55+1.57 (+2.27%) ▲|MRK145.46+1.53 (+1.06%) ▲|MS207.18-7.21 (-3.36%) ▼|MSFT509.20+13.57 (+2.74%) ▲|MU926.10-49.17 (-5.04%) ▼|NEE82.21-0.10 (-0.12%) ▼|NFLX80.75+3.35 (+4.32%) ▲|NKE37.15+0.35 (+0.94%) ▲|NOW143.13+10.60 (+7.99%) ▲|NVDA212.42-5.88 (-2.69%) ▼|ORCL143.85-6.44 (-4.28%) ▼|PEP136.61+0.29 (+0.21%) ▲|PFE27.78+0.06 (+0.20%) ▲|PG146.24+0.97 (+0.67%) ▲|PLTR173.30+6.07 (+3.63%) ▲|PM193.93+2.87 (+1.50%) ▲|QCOM179.12-2.85 (-1.57%) ▼|RTX194.66-3.03 (-1.53%) ▼|SBUX98.86+0.12 (+0.12%) ▲|SCHW106.98-0.27 (-0.25%) ▼|SO86.85-0.33 (-0.37%) ▼|SPG204.76-0.08 (-0.04%) ▼|T26.44+0.38 (+1.46%) ▲|TMO612.15+2.33 (+0.38%) ▲|TMUS183.99+1.66 (+0.91%) ▲|TSLA362.69-2.75 (-0.75%) ▼|TXN264.64-4.06 (-1.51%) ▼|UBER72.76+1.09 (+1.52%) ▲|UNH384.33+7.56 (+2.01%) ▲|UNP284.54+0.14 (+0.05%) ▲|UPS101.69+1.41 (+1.41%) ▲|USB62.38-0.46 (-0.73%) ▼|V376.34+5.89 (+1.59%) ▲|VZ51.30+0.69 (+1.35%) ▲|WFC87.69-2.60 (-2.88%) ▼|WMT109.49+2.34 (+2.18%) ▲|XOM165.46-0.54 (-0.32%) ▼|AAPL334.51+2.24 (+0.67%) ▲|ABBV261.68+4.56 (+1.77%) ▲|ABT102.95+1.00 (+0.98%) ▲|ACN194.28+10.38 (+5.64%) ▲|ADBE264.86+12.63 (+5.01%) ▲|AMAT426.96-29.53 (-6.47%) ▼|AMD494.09-22.05 (-4.27%) ▼|AMGN380.37+3.02 (+0.80%) ▲|AMT177.20-0.65 (-0.37%) ▼|AMZN255.59-1.19 (-0.46%) ▼|AVGO346.64-15.36 (-4.24%) ▼|AXP326.91+2.22 (+0.68%) ▲|BA210.37-0.09 (-0.04%) ▼|BAC60.11-2.59 (-4.12%) ▼|BKNG175.20+1.28 (+0.74%) ▲|BLK1,066.89-12.76 (-1.18%) ▼|BMY64.12+0.48 (+0.75%) ▲|BNY158.30-4.36 (-2.68%) ▼|BRK-B513.81+3.44 (+0.67%) ▲|C133.83-4.99 (-3.59%) ▼|CAT786.08-32.50 (-3.97%) ▼|CL88.34+1.54 (+1.77%) ▲|CMCSA24.98-0.22 (-0.87%) ▼|COF207.37-0.94 (-0.45%) ▼|COP137.69+0.34 (+0.25%) ▲|COST917.05+12.28 (+1.36%) ▲|CRM258.90+11.18 (+4.51%) ▲|CSCO111.49-0.65 (-0.58%) ▼|CVS95.67+1.01 (+1.07%) ▲|CVX213.68-0.39 (-0.18%) ▼|DE681.39+5.65 (+0.84%) ▲|DHR203.41+3.27 (+1.63%) ▲|DIS109.18+2.63 (+2.47%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.37-3.82 (-2.51%) ▼|FDX311.61+0.84 (+0.27%) ▲|GD356.78+0.88 (+0.25%) ▲|GE317.29-6.38 (-1.97%) ▼|GEV873.25-84.02 (-8.78%) ▼|GILD145.74+2.02 (+1.41%) ▲|GM86.41+0.79 (+0.92%) ▲|GOOG345.45+10.00 (+2.98%) ▲|GOOGL348.92+10.42 (+3.08%) ▲|GS990.42-38.76 (-3.77%) ▼|HD310.54+1.80 (+0.58%) ▲|HON199.12-3.25 (-1.60%) ▼|IBM250.89+7.60 (+3.12%) ▲|INTC98.29-4.66 (-4.52%) ▼|INTU338.38+16.81 (+5.23%) ▲|ISRG376.21+7.06 (+1.91%) ▲|JNJ267.88+2.30 (+0.87%) ▲|JPM349.21-7.02 (-1.97%) ▼|KO89.14+0.85 (+0.96%) ▲|LIN464.53-1.70 (-0.36%) ▼|LLY1,145.82+30.12 (+2.70%) ▲|LMT527.84+3.65 (+0.70%) ▲|LOW198.37+1.55 (+0.79%) ▲|LRCX275.82-22.41 (-7.51%) ▼|MA575.04+5.85 (+1.03%) ▲|MCD257.19+4.66 (+1.85%) ▲|MDLZ62.38-0.06 (-0.10%) ▼|MDT93.31+2.35 (+2.58%) ▲|META664.45+16.42 (+2.53%) ▲|MMM162.01-2.96 (-1.79%) ▼|MO70.55+1.57 (+2.27%) ▲|MRK145.46+1.53 (+1.06%) ▲|MS207.18-7.21 (-3.36%) ▼|MSFT509.20+13.57 (+2.74%) ▲|MU926.10-49.17 (-5.04%) ▼|NEE82.21-0.10 (-0.12%) ▼|NFLX80.75+3.35 (+4.32%) ▲|NKE37.15+0.35 (+0.94%) ▲|NOW143.13+10.60 (+7.99%) ▲|NVDA212.42-5.88 (-2.69%) ▼|ORCL143.85-6.44 (-4.28%) ▼|PEP136.61+0.29 (+0.21%) ▲|PFE27.78+0.06 (+0.20%) ▲|PG146.24+0.97 (+0.67%) ▲|PLTR173.30+6.07 (+3.63%) ▲|PM193.93+2.87 (+1.50%) ▲|QCOM179.12-2.85 (-1.57%) ▼|RTX194.66-3.03 (-1.53%) ▼|SBUX98.86+0.12 (+0.12%) ▲|SCHW106.98-0.27 (-0.25%) ▼|SO86.85-0.33 (-0.37%) ▼|SPG204.76-0.08 (-0.04%) ▼|T26.44+0.38 (+1.46%) ▲|TMO612.15+2.33 (+0.38%) ▲|TMUS183.99+1.66 (+0.91%) ▲|TSLA362.69-2.75 (-0.75%) ▼|TXN264.64-4.06 (-1.51%) ▼|UBER72.76+1.09 (+1.52%) ▲|UNH384.33+7.56 (+2.01%) ▲|UNP284.54+0.14 (+0.05%) ▲|UPS101.69+1.41 (+1.41%) ▲|USB62.38-0.46 (-0.73%) ▼|V376.34+5.89 (+1.59%) ▲|VZ51.30+0.69 (+1.35%) ▲|WFC87.69-2.60 (-2.88%) ▼|WMT109.49+2.34 (+2.18%) ▲|XOM165.46-0.54 (-0.32%) ▼|
23.9 C
New York
Monday, September 14, 2026

Tag: collaboration

newssourceFORcompanyinformationcontent1releasesmarket

Zenobē and Brampton lead CA$4 billion initiative to electrify transit bus fleet in landmark UK-Canada collaboration

CA$4B to fund one of North America's largest single zero-emission bus initiatives Initiative expected to support 5,000 direct and indirect jobs across U.K. and...

Rallye 1000 Miglia 2025 : 1, 2, 3, partez !

La plus mythique des courses automobiles du monde fait son grand retour sur les routes d’Italie 
La plus mythique des courses automobiles du monde fait son grand retour sur les routes d’Italie

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Aslan Energy Capital and JIEP Sign Heads of Agreement to Develop East Jakarta’s Renewable-Powered Hyperscale Data Center

JAKARTA, Indonesia, June 14, 2025 /PRNewswire/ -- Aslan Energy Capital (AEC), a Singapore-based developer of clean energy infrastructure, has signed a binding Heads of...

Klein Funding and Bybit Partner to Launch a New Era of Crypto Prop Trading

LONDON, June 14, 2025 /PRNewswire/ -- In 2024, Klein Funding became the first crypto-only prop firm to officially partner with Bybit, one of the world's...

Zinemx Exchange: Upgrading Operational Management System and Building an International Team

DENVER, June 14, 2025 (GLOBE NEWSWIRE) -- Amid the trend of mainstream financial institutions restructuring their human resources systems, Zinemx Exchange has drawn on industry experience to complete a team restructuring and further optimize its operational management system, accelerating its expansion into international markets. David Reynolds, Founder and CEO of Zinemx, emphasized that an efficient team and a compliant management system are essential, and that the new operational structure will provide strong support for the international development of the platform.

Congress Pretends to Care About Privacy. Again.

23andMe, the genetic testing firm that promised to revolutionize personal genomics, is on the auction block. After years of financial struggles, a bankruptcy filing...

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCollaboration

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers